

## Special Issue

# T-cell Immunity and Cancer Immunotherapy

### Message from the Guest Editors

The last decade has witnessed immense progress in cancer therapy, particularly in the field of immunotherapy and the therapeutic potential of the immune system. Much of this progress is attributed to check-point inhibitors targeting the PD-1-mediated exhaustion in T cells. The key reason that neoplasia cells, leading to cancer, are able to establish themselves and progress is their ability to evade the multi-layered immune surveillance mechanisms. Cytotoxic T cells are rendered dysfunctional after chronic exposure to antigen. Dysfunctional T cells, with decreased proliferative capacity, loss of effector function, and overexpression of inhibitory receptors are thus unable to respond to stimulatory cues. One of the main foci in the field of immunotherapy is to harness the potential of T cells to clear cancers. Checkpoint blockades, adoptive T-cell therapy and CART-cell immunotherapies are based on reinvigorating T-cell effector function. The aim of this Special issue focuses on bringing together a collection of high-quality research providing further insight into T-cell biology and novel findings that can impact the endeavor to improve cancer immunotherapy.

---

### Guest Editors

Dr. Nimi Marcel

Department of Molecular Biology, University of California San Diego, San Diego, CA, USA

Dr. Suyasha Roy

Laboratory of Molecular Immunology, National Heart, Lung & Blood Institute, National Institutes of Health, Bethesda, MD, USA

---

### Deadline for manuscript submissions

closed (31 December 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/165645](https://mdpi.com/si/165645)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).